AEON (AEON Biopharma) Moat Score: 2/10 (As of Jun. 29, 2026)


AEON AEON Biopharma Inc AEON
10 GF Score
Price $0.72
! 2 Warning Signs
View Full Analysis

What is AEON Biopharma Moat Score?

AEON Biopharma AEON -0.26% 10 Moat Score is 2 as of Jun. 29, 2026. GuruFocus rates AEON with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 1,401 Biotechnology companies, AEON Biopharma ranks better than 58.1% on this metric.

AEON Biopharma has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

AEON Biopharma has No Moat: AEON Biopharma operates in a competitive biotech industry with limited market share and lacks significant intellectual property or customer switching costs. Its innovation potential is not yet realized, providing minimal competitive advantage.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes AEON Biopharma might have No Moat - Very weak/transient advantages.

AEON Biopharma  (AMEX:AEON) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

AEON Biopharma Moat Score Related Terms

AEON vs ZIVO, CVM, ATOS: Moat Score Comparison

For the Biotechnology subindustry, AEON Biopharma's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AEON Biopharma Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AEON Biopharma's Moat Score distribution charts can be found below:

* The bar in red indicates where AEON Biopharma's Moat Score falls into.


AEON
10GF Score
AEON Biopharma Inc AEON
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
AEON Biopharma (AEON) has a Moat Score of 2 as of Jun. 29, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, AEON Biopharma ranks #587 out of 1401 companies in the Biotechnology industry, placing it in the top 41.9%.
Is AEON Biopharma's Moat Score too high?
AEON Biopharma's current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. AEON Biopharma's value of 2 is 0% at this industry median. Based on the distribution chart, AEON Biopharma ranks #587 out of 1401 companies in the Biotechnology industry, which is above the industry midpoint. Overall, AEON Biopharma has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does AEON Biopharma's Moat Score compare to ZIVO and CVM?
According to the Biotechnology industry distribution chart, AEON Biopharma ranks #587 out of 1401 companies for Moat Score. This puts AEON Biopharma in the upper half of its industry. The industry median Moat Score is 2.00. AEON Biopharma's value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,401 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AEON Biopharma's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AEON Biopharma's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AEON Biopharma stock overvalued right now?
AEON Biopharma (AEON) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. AEON Biopharma's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For AEON Biopharma (AEON), the current Moat Score is 2 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AEON Biopharma Business Description

Address 5 Park Plaza, Suite 1750, Irvine, CA, USA, 92614
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.
10GF Score

Get the complete analysis for AEON

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.72
Price